Latest Lead News

Zoono Group Limited reports strong progress in its shelf-life extension technology trials across multiple continents, with successful UK supermarket trials paving the way for a national roll-out in FY26. Despite a quarterly operating cash outflow, the company expects improved sales and sufficient funding to meet its near-term objectives.

Inca Minerals has secured over 94% ownership of Stunalara Metals, gaining access to the promising Hurricane Project in North Queensland. With an oversubscribed $1.1 million capital raise, maiden drilling is set to begin in Q2 2025, targeting high-grade gold and antimony mineralisation.

Syntara Limited reports significant clinical progress with its lead myelofibrosis drug SNT-5505 and launches a new trial for its next-generation anti-fibrotic skin treatment, supported by a solid $18 million cash reserve.

AustChina Holdings has completed the acquisition of Penwortham Exploration, gaining full control of promising gold-antimony and base metals projects in Tasmania, and has commenced exploration activities in a prolific mining region.

Powerhouse Ventures Limited reports a robust start to 2025, highlighted by strong fund performance, a successful capital raise, and strategic business expansion despite market volatility.

Hartshead Resources has submitted a revised development plan for its Anning and Somerville gas fields, featuring a superior export route via CalEnergy's Saturn Banks pipeline. Supported by a strong cash position and committed partners, the company is exploring innovative funding to optimise project economics.

Flynn Gold Limited reported significant progress in its Tasmanian projects during the March 2025 quarter, highlighted by ongoing diamond drilling at Golden Ridge and discovery of new high-grade gold and silver-lead-zinc targets. The company secured $2.6 million in fresh capital to fund accelerated exploration.

Kalamazoo Resources has secured $800,000 through a share placement to fund critical due diligence at its Ashburton Gold Project and advance exploration across multiple Victorian and Western Australian sites.

Noxopharm Limited has successfully cleared key preclinical hurdles for its SOF-SKN™ lupus drug and expanded its Sofra™ platform collaborations, supported by fresh funding to propel upcoming clinical trials.

archTIS has reported a standout March quarter with record annual recurring revenue, improved gross margins, and strategic growth through the Direktiv acquisition and new international contracts.

Opthea Limited has discontinued its wet AMD development program following Phase III trial failures, slashing its workforce by 65% amid ongoing financial uncertainty and negotiations with investors.

Australian Vanadium Limited reports significant progress across its vertically integrated vanadium strategy, with key project milestones, government approvals, and promising energy storage developments positioning it for growth.